Clinical Research
Comparison of dose distribution of stereotactic radiotherapy plan for vertebral bone metastases of tumors on three devices
Yue Dan, Li Xindi, Quan Xiaoyue, Li Shuchang, Bao Bo, Liu Shixin, Wu Hongfen
Published 2022-09-30
Cite as Chin J Metastatic Cancer, 2022, 05(3): 245-249. DOI: 10.3760/cma.j.cn101548-20211109-00140
Abstract
ObjectiveTo compare dosimetric data of stereotactic body radiation therapy (SBRT) plans with CyberKnife (CK) ,Tomotherapy (Tomo) and volumetric-modulated arc therapy (VMAT) for spine bone metastasisof tumor.
MethodsClinical data of 30 spine bone metastasismalignant tumor patients were retrospectively analyzed. The treatment plans were designed by three apparatuses and transferred to MIM system. Prescription dose: the gross tumor volume was 24 Gy points in 2 times, with the primary goals of Maintaining the max tolerance of the cord (17 Gy) or cauda equine (20 Gy) and the plan target volume (PTV) to receive at least 95% of the prescribed dose. The extraction of parameters mainly included conformity index (CI) , homogeneity index (HI) , gradient index (GI) , target volume coverage, maximum cord (or cauda) dose, and treatment time per fraction.
ResultsPTV mean D2% coverage in VMAT was significantly lager with Tomo (P<0.01 )and CK (P<0.01). The CI and HI in CK were significantly lower with Tomo and VMAT (all P<0.01 ). The best GI was found in CK, followed by Tomo, and VMAT showed the worst (all P<0.01 ). VMAT had the least treatment time vs Tomo (P<0.01 )and CK (P<0.01).
ConclusionsAll three radiotherapy apparatuses can meet the requirement of SBRT for spine bone metastasis of malignant tumor. More rapid dose fall-off could be obtained in CK. VMAT provide better target conformity. The parameters of Tomo are in the middle. The treatment time of VMAT and Tomo are much shorter than CK. The suitable radiotherapy system can be selected according to the characteristics of cases and target areas.
Key words:
Dose distribution; CyberKnife; Tomotherapy; Accelerator volumetric-modulated arc therapy; Tumor metastasis, spine bone/stereotactic body radiotherapy
Contributor Information
Yue Dan
No.5 Department of Radiation Oncology, Jilin Province Cancer Hospital, Changchun 130012, China
Li Xindi
No.5 Department of Radiation Oncology, Jilin Province Cancer Hospital, Changchun 130012, China
Quan Xiaoyue
No.5 Department of Radiation Oncology, Jilin Province Cancer Hospital, Changchun 130012, China
Li Shuchang
Department of Radiotherapy Physics, Jilin Province Cancer Hospital, Changchun 130012, China
Bao Bo
Department of Radiotherapy Center, Jilin Province Cancer Hospital, Changchun 130012, China
Liu Shixin
No.5 Department of Radiation Oncology, Jilin Province Cancer Hospital, Changchun 130012, China
Wu Hongfen
No.5 Department of Radiation Oncology, Jilin Province Cancer Hospital, Changchun 130012, China